Abstract
The DAPA-CKD Trial, designed to assess the effect of dapagliflozin (a sodium–glucose cotransporter 2 [SGLT2] inhibitor) on adverse kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD), with or without type 2 diabetes reported a significant risk reduction (hazard ratio [95% CI] 0.61 [0.51–0.72]) on these outcomes. Data reporting general practitioner (GP) utilization and cost associated with CKD categorized according to 2012 KDIGO recommendations are scarce. We assessed GP visits and costs in a “DAPA-CKD-like population” (estimated glomerular filtration rate [eGFR] 25–75ml/min/1.73m2 and urine-albumin-creatinine-ratio [UACR] 200–5000mg/g) compared to patients categorized according to KDIGO 2012 recommendations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
